Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07030907 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Platinum-resistant Ovarian Cancer, sponsored by Outpace Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT07030907: Recruiting Phase 1 study of Ovarian Cancer and Platinum-resistant Ovarian Cancer, sponsored by Outpace Bio.
NCT07030907 is a Phase 1 study of Ovarian Cancer and Platinum-resistant Ovarian Cancer that is actively recruiting participants, run by Outpace Bio. The registered enrollment target is 30 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07030907, a Phase 1 study of Ovarian Cancer and Platinum-resistant Ovarian Cancer, is actively recruiting participants, sponsored by Outpace Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.
Primary Outcome
Incidence of dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- BIOLOGICAL OPB-101
Study Locations (4)
Michigan
- Karmanos Cancer Institute - Detroit
Minnesota
- University of Minnesota - Minneapolis
New York
- Roswell Park - Buffalo
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2030-05-15 |
| Phase | Phase 1 |
What NCT07030907 shows while recruiting
NCT07030907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which OPB-101 is the first listed.
NCT07030907 reports a single indexed study location in Michigan, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT07030907 about?
NCT07030907 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer". The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants...
What is the current status of trial NCT07030907?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-06-16. Estimated completion is 2030-05-15.
What conditions does trial NCT07030907 study?
This clinical trial studies the following conditions: Ovarian Cancer, Platinum-resistant Ovarian Cancer, Ovarian Cancer Recurrent.
What interventions are being tested in trial NCT07030907?
The interventions under investigation include: OPB-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07030907?
This trial is sponsored by Outpace Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07030907 being conducted?
This trial has 4 study locations across Michigan, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07030907's enrollment target sits among peer trials
30 252nd of 322 higher than 62 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI